옵션 체인은 다양한 행사가격과 만기일에 대한 Eli Lilly의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Eli Lilly에 대한 시장 심리를 평가합니다..

Eli Lilly (NYSE:LLY) 주식, 옵션 체인

Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co

Earnings

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

일라이 릴리 앤 컴퍼니(NYSE:LLY)는 2025년 2월 6일 목요일 개장 전에 4분기 재무 실적을 발표할 예정이다. 

일라이 릴리, 곧 4분기 실적 발표: 최근 애널리스트 의견 변동은?

Health Care

Technicals

Previews

General

일라이 릴리(NYSE:LLY)는 목요일 시장 개장 전에 4분기 실적을 발표할 예정이다. 월스트리트는 주당 순이익(EPS)이 4.94달러, 매출이 136억 6천만 달러에 이를 것으로 예상하고 있다. 주가는 지난 1년 동안 19.26% 상승했으며, 올해 들어 8.24% 상승했다.

4분기 실적 발표를 앞두고 일라이 릴리의 상승세가 주도, 1,000달러에 도달할 수 있을까?

Biotech

Equities

Tech

CRSP

GOOGL

NTLA

ORCL

구글 모기업 알파벳의 자회사인 스타트업 아이소모픽 랩스(Isomorphic Labs)는 올해 연말까지 최초의 인공지능(AI) 설계 의약품의 임상시험을 시작할 예정이다. 주요 기술 기업들이 AI 기반 의료 솔루션에 대한 투자를 늘리면서 제약 개발의 중요한 이정표가 될 것으로 보인다.

알파벳 자회사 아이소모픽 랩스, 올해 말까지 AI가 설계한 신약 임상시험 예정

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live Group

LIBERTY LIVE SERIES B by Liberty Media Corporation

Liberty Media Corporation - Series C Liberty Live Common Stock

Tidal Trust II Defiance Daily Target 2X Long LLY ETF

Guidance

Lilly Exec Says U.S. Prescriptions Of Alzheimer's Drug Kisunla Steadily Increasing Since Launch

Lilly Exec Says In Q4 Zepbound Became The Market Leader In The Anti-Obesity Market As Measured By New Prescriptions

On Thursday, Eli Lilly and Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) stock is trading higher after the company released better-than-expected fourth-quarter earnings and <a target="_blank" href="https://www.benzinga.com/25/02/43505148/what-to-expect-when-eli-lilly-reports-q4-earnings-on-thursday" rel="noreferrer noopener">provided 2025 guidance</a>.
The U.S. pharma giant reported fourth-quarter revenue of $13.53 billion, up 45% year over year, almost in line with the <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus of $13.57 billion</a>.
The increase was driven by a 48% increase in volume, partially offset by a 4% decrease due to lower realized prices.
The volume increase was driven by growth from <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43523303/lilly-reports-full-q4-2024-financial-results-and-provides-2025-guidance" rel="noreferrer noopener">Mounjaro and Zepbound</a>. Lower realized prices were primarily driven by Mounjaro, partially offset by Zepbound and Humalog.
New Products&nbsp;revenue grew by&nbsp;$3.15 billion&nbsp;to&nbsp;$5.64 billion&nbsp;in Q4 2024, led by Zepbound and Mounjaro. Growth Products&nbsp;revenue increased 13% to&nbsp;$5.95 billion,&nbsp;driven by growth in Verzenio and Jardiance, partially offset by lower Trulicity sales.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43053632/fda-approves-expanded-use-of-eli-lillys-ulcerative-colitis-drug-for-crohns-disease" rel="noreferrer noopener">FDA Approves Expanded Use Of Eli Lilly&#8217;s Ulcerative Colitis Drug For Crohn&#8217;s Disease</a>
The company reported an adjusted EPS of $5.32, compared to $2.49 from a year ago, beating the consensus of $4.94.
Mounjaro sales <a target="_blank" href="https://www.benzinga.com/25/01/42976923/eli-lilly-expects-around-55-billion-sales-from-weight-lossdiabetes-drugs-with-overall-topline-growth-of-32-issues-2025-forecast" rel="noreferrer noopener">jumped 60% to $3.53 billion</a>. Sales of Verzenio (a breast cancer drug)&nbsp;increased 36% to&nbsp;$1.56 billion, and sales of diabetes drug Jardiance&nbsp;increased 50% to&nbsp;$1.19 billion.
Zepbound sales reached $1.91 billion, up from $175.8 million a year ago. Trulicity sales fell 25% to&nbsp;$1.25 billion.
Guidance: Eli Lilly forecasts fiscal year 2025 sales of $58 billion-$61 billion versus a consensus of $59.91 billion and $45.04 billion in 2024.
The company adds that the midpoint represents approximately 32% growth compared to 2024, driven by new Lilly medicines such as Zepbound, Mounjaro, Jaypirca, Ebglyss, Omvoh and Kisunla; approvals of new indications for existing Lilly medicines; launches of Mounjaro in additional worldwide markets; and potential launches of new medicines such as imlunestrant for metastatic breast cancer.
The company continues to invest heavily in increasing manufacturing capacity and estimates producing at least 1.6 times the amount of salable incretin doses in the first half of 2025 compared to the first half of 2024.&nbsp;
Eli Lilly forecasts 2025 adjusted EPS of $22.50-$24.00 compared to $12.99 in 2024 and the consensus of $22.69.
Price Action: At last check on Thursday, LLY stock was up 1.11% at 851.49 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/downgrades/25/02/43506847/spotify-analyst-draws-comparison-to-apple-on-scale-pricing" target="_blank" rel="noreferrer noopener">Spotify Analyst Draws Comparison To Apple On Scale, Pricing</a></li>
</ul>
Photo by Ciara Kimsey via Shutterstock

Large Cap

Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines

The following table summarizes the company's 2025 financial guidance:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="3" rowspan="1">2025 Guidance(1)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$58.0 to $61.0 billion</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(Gross Margin - OPEX(2)) / Revenue:</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(reported)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">40.5% to 42.5%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(non-GAAP)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">41.5% to 43.5%</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Other Income/(Expense)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">($700) to ($600) million</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Tax Rate</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Approx. 16%</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Earnings per Share (reported)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$22.05 to $23.55</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Earnings per Share (non-GAAP)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$22.50 to $24.00</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

CORRECTION: Eli Lilly FY25 Outlook: Adj EPS $22.50-$24.00 vs $22.69 Est; Sales $58.00B-$61.00B vs $59.91B Est

Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) reported quarterly earnings of $5.32 per share which beat the analyst consensus estimate of $4.94 by 7.69 percent. This is a 113.65 percent increase over earnings of $2.49 per share from the same period last year. The company reported quarterly sales of $13.53 billion which missed the analyst consensus estimate of $13.57 billion by 0.28 percent. This is a 44.69 percent increase over sales of $9.35 billion the same period last year.

Eli Lilly Q4 2024 Adj EPS $5.32 Beats $4.94 Estimate, Sales $13.53B Miss $13.57B Estimate

U.S. stock futures rose on Thursday following Wednesday&#8217;s advances as investors digest tariff pauses by the Trump administration amid earnings reports. All four benchmark indices were trading higher.
Heavyweight Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) along with Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Fortinet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>), Thomson Reuters Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRI#NYSE">TRI</a>), Cloudflare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) and Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) are a few companies that will report their earnings today.
The 10-year Treasury yield stood at 4.44%, while the two-year yield was at 4.21%. According to the CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>, there is an 85.5% chance that the Federal Reserve will keep interest rates unchanged for the March meeting.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.20%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.24%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.36%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.33%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) both experienced positive premarket trading on Thursday. SPY rose 0.22% to $605.57, and QQQ advanced 0.22% to $528.03, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
Real estate, information technology, and financial sectors led the <a href="https://www.benzinga.com/news/earnings/25/02/43520435/dow-rises-over-300-points-as-nvidia-surges-investor-sentiment-improves-but-greed-index-remains-in-fear-zone">gains</a> in U.S. stocks on Wednesday, however, communication services and consumer discretionary stocks declined, bucking the overall market trend. 
Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares jumped over 5% following positive results from Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) and Google&#8217;s increased FY25 capital expenditure guidance. The Walt Disney Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) also reported better-than-expected first-quarter financial results.
On the economic front, the U.S. trade deficit widened to $98.4 billion in December, exceeding market expectations of $96.6 billion and up from a revised $78.9 billion in November. The ISM services PMI fell to 52.8 in January, below the estimated 54.3 and a revised 54 in December.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.19%</td>
<td>19,692.33</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.39%</td>
<td>6,061.48</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.71%</td>
<td>44,873.28</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.14%</td>
<td>2,316.23</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
Despite recent market volatility, a &#8220;buy the dip&#8221; mentality remains prevalent among investors, according to Liz Ann Sonders, chief investment strategist at Schwab. According to Schwab&#8217;s <a href="https://international.schwab.com/story/stock-market-update-open">daily commentary</a>, Sonders noted that money continues to seek opportunities, with &#8220;stealthy, quiet participation&#8221; emerging in sectors beyond the &#8220;Magnificent Seven&#8221; tech stocks.
She emphasized that this diversification is a healthy sign, predating the recent tariff-related concerns. However, Sonders cautioned that the market should brace for continued &#8220;rapid-fire sector rotations,&#8221; citing the recent movement of tech and defensive stocks. These sector-related gyrations, she predicted, are likely to persist for some time.
Scott Wren, the senior global market strategist at Wells Fargo <a href="https://www.wellsfargoadvisors.com/research-analysis/commentary/stock-market-commentary.htm">said</a> that he views the tariff threats so far as bargaining chips the U.S. president is using to encourage agreement from the leaders of various countries. He highlighted that &#8220;bringing more manufacturing back to the U.S., particularly from China and Mexico, is a goal but will take time.&#8221;
The market momentum remains positive overall, though the numerous policy changes under a potential second Trump administration are likely to fuel further volatility, said Louis Navellier of Navellier &amp; Associates.
He highlighted the new administration&#8217;s apparent push for lower interest rates and energy prices, noting that both appear to be underway and are positive indicators for economic growth.
However, tariffs remain a significant wildcard due to the unpredictable nature of potential responses, particularly from China, a major U.S. trade partner. Navellier pointed out that earnings have been encouraging, and smaller capitalized stocks are performing well. Looking ahead, he suggests that if current trends continue, the Federal Reserve could eventually implement rate cuts, which would further boost market momentum.
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Thursday:
<ul>
<li>Initial jobless claims till Feb. 1 and the U.S. productivity data for the fourth quarter will be out at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Fed Governor Christopher Waller will speak at 2:30 p.m. and Dallas Fed President Lorie Logan will speak at 5:10 p.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) advanced 0.61% in premarket on Thursday ahead of its earnings, which will be released after market close. Analysts expect it to report quarterly earnings of $1.49 per share on revenue of $187.31 billion.</li>
</ul>
<ul>
<li>Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) was down 0.54% as Wall Street expects it to report quarterly earnings of $2.32 per share on revenue of $9.83 billion before the opening bell.</li>
</ul>
<ul>
<li>Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) slipped 0.27% ahead of its earnings before the opening bell. Analysts expect it to report quarterly earnings of $1.46 per share on revenue of $11.57 billion.</li>
</ul>
<ul>
<li>Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) slid 0.73% as Wall Street expects it to report quarterly earnings of $5.08 per share on revenue of $13.43 billion before the opening bell.</li>
</ul>
<ul>
<li>Arm Holdings Plc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) declined 5.08% despite reporting better-than-expected third-quarter financial results for fiscal year 2025 as it narrowed its next quarter and full-year&#8217;s guidance.</li>
</ul>
<ul>
<li>Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) fell 5.09% despite upbeat fourth-quarter financial results but forecasted a tougher year.</li>
</ul>
<ul>
<li>Sangoma Technologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANG#NASDAQ">SANG</a>) was down 5.07% after it reported a loss in the second quarter and missed revenue estimates.</li>
</ul>
<ul>
<li>Rani Therapeutics Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) was up 40.97% after successful preclinical data for oral delivery of semaglutide which is used to treat type-2 diabetes.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 0.59% to hover around $71.45 per barrel.
The gold spot index was down by 0.29% to $2,859.30 per ounce. The Dollar Index was down 0.39% at 107.998 level.
Asian markets were trading higher on Thursday. China's CSI 300, Hong Kong's Hang Seng, Australia's ASX 200, South Korea's Kospi, and Japan's Nikkei 225 index advanced. European markets were mostly higher in trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/43491799/meta-ai-models-clearly-behind-deepseek-says-analysts-after-mark-zuckerberg-admitted-deepseek-did-some-novel-things-were-still-digesting">Meta AI Models ‘Clearly Behind' DeepSeek, Says Analyst After Mark Zuckerberg Admits DeepSeek Did Some Novel Things ‘We're Still Digesting'</a></li>
</ul>
Photo courtesy: Shutterstock

Analyst Color

Futures

Economics

AMZN

FTNT

NVDA

RANI

RBLX

SANG

US Stocks Likely To Open Higher Ahead Of Amazon's Earnings: 'Buy The Dip' Mentality Remains Prevalent, Says Analyst

AAMI

AFRM

AGCO

AMRK

APTV

BILL

CCEC

CIGI

CLFD

CLSK

CRNC

CTLP

DOCS

EMBC

ENTG

EXPE

EXPO

FARM

FBIN

GOOS

GPRO

GTES

GTIM

HUBG

IBEX

IDCC

IIIV

ILMN

INTR

KVUE

LADR

LESL

Laboratory Corporation Of America Holdings

LION

LITE

LIVE

LQDT

LSPD

LTRX

MAGN

MATW

MCFT

MCHP

MKTX

MPWR

MSGE

MTSI

Earnings Scheduled For February 6, 2025

Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) will release its fourth-quarter financial results, before the opening <a href="https://www.benzinga.com/quote/LLY/earnings">bell, on Thursday, Feb. 6, 2025.</a>
Analysts expect the Indianapolis, Indiana-based company to report quarterly earnings at $5.08 per share, up from $2.49 per share in the year-ago period. Eli Lilly projects quarterly revenue of $13.43 billion, compared to $9.35 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
In January, just before the JP Morgan healthcare conference, Eli Lilly announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth compared to the previous year versus the consensus of $45.50 billion.
Eli Lilly shares gained 2% to close at $842.18 on Wednesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/LLY/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Wells Fargo analyst Mohit Bansal maintained an Overweight rating and cut the price target from $1,000 to $970 on Jan. 28, 2025. This analyst has an accuracy rate of 72%.</li>
<li>B of A Securities analyst Tim Anderson reinstated a Buy rating and a price target of $997 on Dec. 10, 2024. This analyst has an accuracy rate of 65%.</li>
<li>Barclays analyst Carter Gould maintained an Overweight rating and cut the price target from $1,025 to $975 on Oct. 31, 2024. This analyst has an accuracy rate of 60%.</li>
<li>Morgan Stanley analyst Terence Flynn reiterated an Overweight rating with a price target of $1,106 on Aug. 27, 2024. This analyst has an accuracy rate of 67%.</li>
<li>BMO Capital analyst Evan Seigerman maintained an Outperform rating and raised the price target from $1,001 to $1,101 on Aug. 9, 2024. This analyst has an accuracy rate of 62%.</li>
</ul>
Considering buying LLY stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="579" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06030204/image-47-1024x579.png" alt="" class="wp-image-768704" style="width:564px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06030204/image-47-1024x579.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06030204/image-47-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06030204/image-47-768x434.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06030204/image-47.png 1127w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43493237/jim-cramer-this-health-care-stock-is-a-winner-buy-bitcoin-instead-of-coinbase">Jim Cramer: This Health Care Stock Is A &#8216;Winner,&#8217; Buy Bitcoin Instead Of Coinbase</a></li>
</ul>

Eli Lilly Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) will be reporting its fourth-quarter earnings on Thursday. Wall Street expects $4.94 in EPS and $13.66 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=LLY" target="_blank" rel="noreferrer noopener"> before market hours</a>.
The stock is up 19.23% over the past year, 8.22% YTD.
Let&#8217;s look at what the charts indicate for Eli Lilly stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/25/02/43459558/novo-nordisk-faces-investor-concerns-over-hybrid-cagrisema-trial-results-for-weight-loss">Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss</a>
<h2 class="wp-block-heading">LLY Stock Strongly Bullish Ahead Of Q4 Earnings</h2>
&nbsp;LLY stock is exhibiting strong bullish momentum, with its share price of $841.78 trading above the five-day, 20-day and 50-day exponential moving averages. This sustained buying pressure suggests continued upside potential. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="626" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05124101/Screenshot-2025-02-05-at-11.02.49-PM.png" alt="" class="wp-image-767704" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05124101/Screenshot-2025-02-05-at-11.02.49-PM.png 626w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05124101/Screenshot-2025-02-05-at-11.02.49-PM-300x235.png 300w" sizes="(max-width: 626px) 100vw, 626px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020525&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
LLY stock also remains above key short- and medium-term simple moving averages, further reinforcing the bullish trend.
LLY stock has also crossed over its 200-day simple moving average of $841.52. The stock has broken the resistance level and signals bullish momentum being set for the long term. The Moving Average Convergence Divergence indicator at 12.09 supports the bullish outlook, while the Relative Strength Index at 64.87 signals that the stock is approaching overbought territory but still has room for further gains. 
Investors should monitor any new resistance level being created to assess the extent to which they can expect the bullish trend to extend further.
<h2 class="wp-block-heading">Eli Lilly Analysts See 27% Upside</h2>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/LLY/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on Eli Lilly stock stands at a Buy with a price target of $955.21. The latest analyst ratings from Truist Securities, Wells Fargo and Citigroup imply a 26.97% upside for LLY stock, with an average price target of $1066.
LLY Stock Price Action: Eli Lilly stock was up 1.9% at $842.30 at the time of publication Wednesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/43403416/is-big-pharma-about-to-win-goldman-sachs-weighs-in-on-340b-and-medicaid-shifts">Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts</a></li>
</ul>
Photo: Shutterstock

Eli Lilly Bulls Take Charge Ahead Of Q4 — Can It Reach $1000?

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on&nbsp;February 6. As per data from Benzinga Pro, the Wall Street estimates sales of $13.7 billion, with <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">adjusted EPS of $4.94</a>.
In January, just before the&nbsp;JP Morgan healthcare conference,&nbsp;Eli Lilly announced that it expects 2024 full-year worldwide revenue to be approximately&nbsp;$45.0 billion, representing a 32% growth compared to the previous year versus the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43013223/eli-lilly-adjusts-outlook-ceo-david-ricks-explains-revenue-shortfall" rel="noreferrer noopener">consensus of $45.50 billion</a>.
The company&#8217;s expected 2024 revenue is&nbsp;$400 million, or about 3%, below the guidance range issued during the&nbsp;third-quarter earnings. The guidance includes approximately&nbsp;$3.5 billion&nbsp;for Mounjaro and $1.9 billion&nbsp;for Zepbound.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/01/43403416/is-big-pharma-about-to-win-goldman-sachs-weighs-in-on-340b-and-medicaid-shifts" rel="noreferrer noopener">Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts</a>
Analysts are tracking Eli Lilly&#8217;s expected increase in sales and profit in the first full quarter, during which its weight-loss drugs ceased to be in shortage.
In October 2024, the FDA determined that&nbsp;Eli Lilly&#8217;s tirzepatide injection shortage <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42783449/eli-lilly-joins-fda-lawsuit-over-compounded-obesity-drugs-seeks-swift-end-and-to-protect-its-interests" rel="noreferrer noopener">had been resolved</a>.
The U.S. pharma giant reported third-quarter revenue of $11.44 billion, up 20% year over year, but it missed the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua" rel="noreferrer noopener">consensus of $12.10 billion</a>. Mounjaro sales more than doubled to $3.11 billion from $1.41 billion a year ago.
Sales of Verzenio (a breast cancer drug)&nbsp;increased 32% to&nbsp;$1.37 billion, and sales of diabetes drug Jardiance&nbsp;fell 2% to&nbsp;$686.4 million.
Zepbound sales reached $1.26 billion. Trulicity sales fell 22% to&nbsp;$1.30 billion.
Rival Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) stock is trading higher. On Wednesday, the company reported sales of roughly $12.25 billion (85.68 billion Danish kroner) for the fourth quarter of 2024, beating the consensus of $11.34 billion (<a target="_blank" href="https://www.benzinga.com/25/02/43491991/novo-nordisk-records-more-than-double-wegovy-sales-in-q4-seeks-regulatory-approval-for-hybrid-weight-loss-drug-in" rel="noreferrer noopener">79.73 billion Danish Kroner</a>).
GLP-1 diabetes sales increased by 12%, and Obesity care sales increased by 91%.
Ozempic sales increased 12% to 33.85 billion Danish kroner, and Wegovy sales more than doubled to 19.87 billion Danish kroner.
According to Reuters, investors and analysts expect Eli Lilly to outline its strategy for promoting Zepbound this year as it aims to compete with Wegovy, a more established drug.
Zepbound holds a little over 50% of the market, according to IQVIA data cited by an analyst. Eli Lilly began advertising the drug in November.
Price Action: LLY stock is up 2.19% at $843.59 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43496469/aircraft-manufacturer-embraer-bags-7b-order-stocks-surge" target="_blank" rel="noreferrer noopener">Embraer Lands Record $7 Billion Flexjet Order, Stock Jumps</a></li>
</ul>
Image by Mohammed_Al_Ali via Shutterstock

What To Expect When Eli Lilly Reports Q4 Earnings On Thursday?

In December, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) released headline results from the REDEFINE 1 Phase 3 trial in the&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42613036/novo-nordisks-hybrid-weight-loss-drug-falls-short-on-expectations-stock-plunges" rel="noreferrer noopener">global REDEFINE program</a>.
When evaluating the effects of treatment if all people adhered to treatment, people treated with CagriSema achieved a weight loss of 22.7% after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and 2.3% with placebo alone.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43055832/novo-nordisks-higher-dose-of-wegovy-shows-weight-loss-of-around-21-phase-3-data-shows" rel="noreferrer noopener">Novo Nordisk's Higher Dose Of Wegovy Shows Roughly 21% Weight Loss</a>
In interviews with Reuters, some investors, analysts, and trial participants have raised concerns over CagriSema's side effects, dosing protocol, and effectiveness compared to Eli Lilly And Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">Zepbound (Mounjaro)</a>.
Five patients from the REDEFINE-1 and REDEFINE-4 trials interviewed by Reuters said CagriSema helped them lose weight rapidly, but side effects, such as nausea, constipation, and fatigue, were significant.
The weaker-than-expected trial data has raised doubts about Novo Nordisk's ability to compete with Eli Lilly's weight-loss drug.
In November, Novo Nordisk said its hybrid drug, CagriSema, aims to reduce weight by 25% without&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41706292/as-race-to-best-miracle-obesity-drug-heats-up-ozempic-maker-novo-nordisk-tests-new-hybrid-drug-th" rel="noreferrer noopener">added side effects</a>.
A key issue emerging from the trial is that only 57.3% of patients reached the highest dose of CagriSema. Novo has not clarified whether this was due to intolerable side effects or effective weight loss at lower doses.
Investors and analysts were also surprised by the study's flexible dosing protocol, which allowed participants to adjust their dosage instead of following a strict schedule.
Some believe this contributed to the low uptake of the highest dose and may have affected overall trial results.
Novo Nordisk will release its fourth quarter 2024 earnings on Wednesday. Analysts expect sales of DKK 79.73 billion and EPS of DKK 5.86 as per data from <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">Benzinga Pro</a>.
Reuters, citing a Barclays analyst, noted that the lack of clarity has fueled negative sentiment, with concerns that CagriSema may be less effective than Eli Lilly's Zepbound, have worse tolerability, and be more difficult to manufacture.
Last week, Novo Nordisk&nbsp;released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration.
When evaluating the effects of treatment if all people adhered to treatment&nbsp;from a mean baseline body weight of 92.7 kg, people treated with amycretin achieved an estimated body weight loss of 9.7% on 1.25mg (20 weeks), 16.2% on 5mg (28 weeks) and 22.0% on <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43187095/novo-nordisks-weekly-amycretin-delivers-up-to-22-weight-loss-in-study-stock-soars" rel="noreferrer noopener">20mg (36 weeks)</a>.
Price Action: At last check on Tuesday, NVO stock was down 0.94% to $81.87 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/02/43444040/dan-loebs-third-point-trims-amazon-microsoft-meta-as-tech-stocks-climb" target="_blank" rel="noreferrer noopener">Dan Loeb's Third Point Trims Amazon, Microsoft, Meta As Tech Stocks Climb</a></li>
</ul>
Photo via Shutterstock

Media

Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss

Truist Securities analyst Srikripa Devarakonda maintains Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with a Buy and raises the price target from $1029 to $1038.

Truist Securities Maintains Buy on Eli Lilly, Raises Price Target to $1038

Medicaid funding, totaling approximately $900 billion per year and serving around 72 million participants, and the 340B program <a target="_blank" href="https://www.benzinga.com/25/01/43294006/trump-white-house-blames-outage-for-medicaid-website-lockout-we-have-confirmed-no-payments-have-been-affected" rel="noreferrer noopener">are key focus areas for potential healthcare reforms.</a>
Goldman Sachs analyst Salveen Richter, however, warns that federal Medicaid cuts could lead to stricter policies and lower drug coverage.
Per Richter, the 340B program is currently facing increased scrutiny, with proposed reforms that could potentially benefit biopharma companies by limiting eligibility for drug discounts, which would enable &#8220;transfer of profits&#8221; from providers back to biopharma.
This shift could positively impact major biopharma companies with high exposure to 340B drugs, such as Merck &amp; Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) and Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>).
However, the specifics of these reforms are still uncertain, which could cause &#8220;volatility&#8221; in the healthcare sector until more details are released.
At the same time, Medicaid funding and eligibility changes are under consideration as potential cost-saving measures by the new administration.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43392796/abbvie-jumps-after-q4-earnings-beat-skyrizi-and-rinvoq-boom-offsets-humira-decline" rel="noreferrer noopener">AbbVie Jumps After Q4 Earnings Beat, Skyrizi And Rinvoq Boom Offsets Humira Decline</a>
These changes could have negative effects on biopharma companies with significant Medicaid drug exposure, including AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), Gilead Sciences, and Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), whose top Medicaid drugs make up a large percentage of their US sales.
Overall, for the 340B program, the analyst sees potential policy/legal outcomes that would move dynamics towards a transfer of profits from providers to biopharma companies as a positive for much of the biopharma sector.
Meanwhile, potential Medicaid changes could create &#8220;potential headwinds&#8221; for healthcare providers and biopharma companies, though the exact effects remain uncertain.
The healthcare industry is awaiting further clarity on these proposed policy changes and their implications.
Overall, the analyst notes that exposure to Medicaid and 340B can vary widely by product and indication.
The top three highest-spend drugs for Medicaid (as of 2022) are AbbVie&#8217;s Humira, Gilead&#8217;s Biktarvy and Eli Lilly&#8217;s Trulicity for type 2 diabetes and cardiovascular disease.
For these drugs, Medicaid and 340B spending represented ~15-30% of the drugs' FY22 and FY23 revenue.
Further, 340B impact may vary for different methods of administration within the same indication &#8211; for example, Gilead&#8217;s expects lower 340B exposure for injectables for PrEP than for daily orals &#8211; and expansion of eligibility for 340B discounts may have an outsized impact on certain therapeutics over others.
Overall, 340B reform would serve as a tailwind to biopharma, as the aforementioned initiatives are generally intended to limit access to the statutory discount.
On the other hand, spending cuts to Medicaid could have a negative impact to volume if they have the effect of reducing coverage, the analyst writes.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43308041/chevron-ge-vernova-engine-no-1-bet-big-on-ai-power-but-is-it-too-late" target="_blank" rel="noreferrer noopener">Chevron, GE Vernova Bet Big On AI Power: Data Centers To Consume Enough Natural Gas To Power 3.5 Million Homes</a></li>
</ul>

Movers

ABBV

GILD

Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts

Deep-pocketed investors have adopted a bullish approach towards Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LLY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 39 extraordinary options activities for Eli Lilly. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 33% bearish. Among these notable options, 9 are puts, totaling $927,681, and 30 are calls, amounting to $1,799,357.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $550.0 to $910.0 for Eli Lilly over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Eli Lilly's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Eli Lilly's significant trades, within a strike price range of $550.0 to $910.0, over the past month.
<h3>Eli Lilly Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738339274_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$98.5</td>
<td>$96.85</td>
<td>$98.5</td>
<td>$840.00</td>
<td>$551.7K</td>
<td>471</td>
<td align="right">61</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$66.1</td>
<td>$64.4</td>
<td>$64.35</td>
<td>$770.00</td>
<td>$321.7K</td>
<td>291</td>
<td align="right">51</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$18.95</td>
<td>$18.15</td>
<td>$18.5</td>
<td>$850.00</td>
<td>$283.0K</td>
<td>1.1K</td>
<td align="right">157</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/07/25</td>
<td>$23.75</td>
<td>$22.6</td>
<td>$23.16</td>
<td>$825.00</td>
<td>$185.2K</td>
<td>318</td>
<td align="right">107</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$116.95</td>
<td>$113.95</td>
<td>$115.65</td>
<td>$900.00</td>
<td>$69.3K</td>
<td>108</td>
<td align="right">68</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
After a thorough review of the options trading surrounding Eli Lilly, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Eli Lilly's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 499,967, the LLY's price is down by -0.02%, now at $823.09. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 6 days.</li>
</ul>
<h3>What The Experts Say On Eli Lilly</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $1080.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Eli Lilly, targeting a price of $1190. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Eli Lilly with a target price of $970. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Eli Lilly, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Eli Lilly Unusual Options Activity

Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has outperformed the market over the past 20 years by 6.03% on an annualized basis producing an average annual return of 14.45%. Currently, Eli Lilly has a market capitalization of $740.34 billion. 
Buying $100 In LLY: If an investor had bought $100 of LLY stock 20 years ago, it would be worth $1,476.91 today based on a price of $823.23 for LLY at the time of writing.
<h3>Eli Lilly's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738280753_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Robert F. Kennedy Jr., President Donald Trump's pick for health secretary, addressed a wide range of medical-related topics on Wednesday during a confirmation hearing with <a href="https://www.benzinga.com/25/01/43306674/trumps-hhs-pick-robert-kennedy-jr-begins-senate-confirmation-hearings">the Senate Finance Committee.</a>
While Kennedy&#8217;s tone in each back-and-forth varied, depending on the senator, it was evident that Kennedy&#8217;s role in the new administration would have a tremendous impact on both pharma and insurance stocks.
<h3 class="wp-block-heading">Drug Price Negotiation</h3>
During one exchange about the high cost of drugs with Senator Catherine Cortez Masto (D-NV), Kennedy said: "Senator, my understanding is that the White House issued an executive order, I believe today, supporting the drug negotiations under the I.R.A. President Trump was very aggressive during his first term about negotiating drug prices."
In reality, Trump has not signed an executive order on the topic since he was sworn into office. A Wednesday news <a href="https://www.cms.gov/newsroom/press-releases/cms-statement-lowering-cost-prescription-drugs" target="_blank" rel="noreferrer noopener">release</a> from the Centers for Medicare and Medicaid Services said that lowering the cost of prescription drugs for Americans &#8220;a top priority&#8221; for the Trump administration and that he would work to improve the transparency of the negotiation process.
Perhaps Kennedy was recalling Trump&#8217;s first term. In 2020, then-45th President Trump <a href="https://www.benzinga.com/general/biotech/20/09/17482940/trump-signs-executive-order-to-lower-us-drug-prices-after-negotiations-with-drugmakers-fail">signed an executive order</a> on U.S. Medicare drug prices intending to reduce costs. Industry leaders, including Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) CEO Albert Bourla, criticized the move. Pfizer was seeking regulatory approval to expand its late-stage vaccine trial at the time.
If Trump signs such an order, it would be a rare show of support from his camp for a Biden-era initiative. In addition to Pfizer, it would also impact major companies like Bristol Myers Squibb, Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), Novartis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) and AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>).
Last month, the Biden administration <a href="https://www.benzinga.com/25/01/43062779/popular-ozempic-wegovy-selected-for-next-round-of-medicare-drug-price-negotiations">identified the next 15 drugs</a> as subject to negotiation. The list included Ozempic and Wegovy — two expensive drugs for diabetes and obesity owned by Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
See Also: <a href="https://www.benzinga.com/25/01/43306674/trumps-hhs-pick-robert-kennedy-jr-begins-senate-confirmation-hearings">RFK Jr. Is A &#8216;Predator&#8217; Unfit For Office, Caroline Kennedy Says </a>
<h3 class="wp-block-heading">Insurance Providers</h3>
According to the <a href="https://www.nytimes.com/live/2025/01/29/us/rfk-jr-health-senate-hearing">New York Times</a>, Kennedy wasn&#8217;t exactly familiar with Medicare and Medicaid, but expressed support for Medicare Advantage, where private insurers provide coverage for elderly Americans.
Kennedy also called out what he considered to be &#8220;rapacious behavior by insurance companies." He even suggested he would support some of the efforts undertaken during the Biden administration to crack down on abusive tactics like denying care and overcharging the government.
Traders would be wise to keep an eye on how insurance stocks — especially those tied to Medicaid and Medicare providers — react if Kennedy is sworn in. The major players in this space include: 
UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), the largest Medicare Advantage insurer in the U.S.; Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>); Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), one of the largest Medicaid managed care organizations; Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>); CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>); Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>); and Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>).
What&#8217;s Next: Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people.
The title also puts him in charge of the Food and Drug Administration, the National Institutes of Health and the Centers for Disease Control and Prevention.
He will appear before the Senate Committee on Health, Education Labor and Pensions on Thursday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/25/01/43216758/well-go-as-far-as-im-allowed-trumps-plan-with-immigrants-starts-with-1-million-deportations" target="_blank" rel="noreferrer noopener">‘We'll Go As Far As I'm Allowed': Trump's Plan With Immigrants Starts With 1 Million Deportations</a></li>
</ul>
Image: Shutterstock

Politics

Insurance

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) is a &#8220;very <a href="https://www.benzinga.com/quote/FSLR/earnings">inexpensive&#8221; stock</a>.
First Solar, meanwhile, will report financial results for the fourth quarter and full year ended Dec. 31, 2024, after the closing bell on Tuesday, Feb. 25, 2025.
<h3 class="wp-block-heading">Shares His Views On These Health Care Stocks</h3>
When asked about Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), Cramer said he prefers Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
In the recent news, Viking Therapeutics, on Jan. 8, announced the initiation of Phase 2 VENTURE-oral dosing trial of VK2735 tablet formulation in patients with obesity.
&#8220;This group is just not strong enough, that includes this one. Let's give it a pause for a second,&#8221; Cramer said when asked about RadNet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>). &#8220;It was a great stock for a long time, I need to see a real bottom.&#8221;
Barclays analyst Andrew Mok, on Jan. 22, maintained RadNet with an Overweight rating and lowered the price target from $85 to $74, while Truist Securities analyst David Macdonald reiterated the stock with a Buy and slashed the price target from $94 to $88.
<h3 class="wp-block-heading">Likes This Industrial Stock Very Much</h3>
The &#8220;Mad Money&#8221; host said he likes Waste Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) very much, adding that it's an &#8220;absolutely terrific&#8221; stock. He added, &#8220;I would start a position right now.&#8221;
Supporting his view, Scotiabank analyst Konark Gupta, on Monday, upgraded Waste Management from Sector Perform to Sector Outperform and raised the price target from $225 to $250.
Price Action:
<ul>
<li>Viking Therapeutics shares gained 2.6% to settle at $34.32 on Tuesday.</li>
<li>First Solar shares fell 2.5% to close at $160.24 during the session.</li>
<li>RadNet shares gained 4.2% to settle at $65.94 on Tuesday.</li>
<li>Waste Management shares rose 0.01% to settle at $213.65 on Tuesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43263799/wall-streets-most-accurate-analysts-spotlight-on-3-tech-telecom-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Tech &amp; Telecom Stocks Delivering High-Dividend Yields</a></li>
</ul>
Image: Shutterstock

FSLR

RDNT

VKTX

Jim Cramer: This Industrial Stock Is 'Absolutely Terrific', First Solar Is 'Very Inexpensive'

Note: This story has been updated with additional details on recent moves by tech titans.
Rep. Marjorie Taylor Greene (R-Ga.) <a href="https://www.benzinga.com/insights/government/25/01/43271358/georgia-rep-marjorie-taylor-greene-bought-over-1k-worth-of-asml-holding-stock-heres-what-you-">disclosed</a> a series of new trades as President Donald Trump&#8216;s equations with the leaders of Big Tech companies and other firms evolve during his second term. Greene&#8217;s portfolio shows the addition of 14 stocks and U.S. Treasuries, in a disclosure dated Jan. 27.
What Happened: The Republican politician, Greene, who has been the representative of Georgia&#8217;s 14th congressional district since 2021 has added a total of five lots of Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), with a transaction value of $1,001-$15,000 each to her portfolio in 2025, with the most recent trade on Jan. 21.
According to Benzinga&#8217;s government trades <a href="https://www.benzinga.com/gov-trades/members/marjorie-taylor-greene">tracking tool</a>, Taylor Greene also owns two lots of Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), with the recent purchase valued at $1,001-$15,000 on Jan. 21.
Whereas, Green purchased Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) for the first time in 2025 on Jan. 21, valued at around $1,001-$15,000, ahead of the Federal Reserve&#8217;s interest rate decision
Here&#8217;s a summary of Greene&#8217;s trades on Jan. 21:
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Stocks/Bonds Purchased</td>
<td>Amount</td>
</tr>
<tr>
<td>Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Cardinal Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Devon Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Eli Lilly And Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Kinder Morgan Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>NextEra Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Norfolk Southern Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Occidental Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Old Dominion Freight Line Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Palo Alto Networks Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>)</td>
<td>$1,001-$15,000</td>
</tr>
<tr>
<td>US Treasury Bills</td>
<td>$50,001-$100,000</td>
</tr>
</tbody>
</table>
</figure>
While she owned two lots of Palo Alto Networks worth $1,001-$15,000 and one lot of U.S. Treasury bills worth $100,001-$250,000, all other purchases in the list are the most recent, dated Jan. 21.
See Also: <a href="https://www.benzinga.com/25/01/43295664/nvidia-supplier-asml-beats-q4-earnings-as-ceo-says-ai-is-key-driver-for-growth-is-it-a-buy-sell-or-hold-heres-what-technical-analysis-suggest">Nvidia Supplier ASML Beats Q4 Earnings Estimates, CEO Says &#8216;AI Is Key Driver For Growth:&#8217; Buy, Sell, Or Hold? Here&#8217;s What Technical Analysis Suggests </a>
Apart, from these stocks, she had investments worth $1,001-$15,000 in three lots of Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>), and Caterpillar Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) in 2025.
She also held one lot worth $1,001-$15,000 in Home Depot Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>), iShares Bitcoin Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>), Southern Copper Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>), Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>), and two lots worth the same in United Parcel Service Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) and Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), in 2025.
Lastly, in 2025, she owned four lots of the same amount in JPMorgan Chase &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) and Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
Why It Matters: Members of Congress, both senators and representatives must publicly <a href="https://www.benzinga.com/insights/government/25/01/43271358/georgia-rep-marjorie-taylor-greene-bought-over-1k-worth-of-asml-holding-stock-heres-what-you-">disclose</a> any personal stock trades they make. This means they have to file a report whenever they buy or sell stock.
The STOCK Act, which became law in 2012, requires these reports to be filed within 45 days of the transaction and also mandates monthly disclosures of their financial holdings. This law aims to prevent insider trading by making sure Congress members don&#8217;t use their privileged information for personal profit in the stock market.
Major tech titans, including Tesla&#8217;s Elon Musk, Amazon&#8217;s Jeff Bezos, Meta&#8217;s Mark Zuckerberg, Apple&#8217;s Tim Cook, And Google&#8217;s Sundar Pichai have been visiting President <a href="https://www.benzinga.com/news/25/01/42935628/mark-zuckerberg-meets-donald-trump-at-mar-a-lago-mending-fences-ahead-of-gop-white-house-return">Trump's Mar-a-Lago </a>residence, reportedly seeking to shape future tech policies. 
Following Trump's victory in the 2024 U.S. presidential election, major tech leaders are shifting their strategies to align with the new administration. Zuckerberg <a href="https://www.benzinga.com/tech/25/01/42779753/mark-zuckerbergs-meta-replaces-global-affairs-chief-nick-clegg-with-republican-joel-kaplan-ahead-of-trump-inauguration">appointed Republican</a> Joel Kaplan to lead policy and donated $1 million. Google, Amazon, and Apple followed suit with similar contributions. Microsoft's Satya Nadella, who reportedly gave $500,000 to Trump&#8217;s first inauguration, is also engaging with the new administration to strengthen relations.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43263070/deepseek-buzz-batters-big-tech-but-this-analyst-says-buy-the-dip-heres-a-list-of-top-five-semiconductor-etfs-with-the-lowest-expense-rations-that-investors-could-consider">DeepSeek Buzz Batters Big Tech But This Analyst Says &#8216;Buy The Dip:&#8217; Here&#8217;s Are Top 5 Semiconductor ETFs With The Lowest Expense Ratios That You Can Consider </a></li>
</ul>
Photo courtesy: Shutterstock

Market Summary

Sector ETFs

Bonds

ETFs

GOOG

IBIT

INTC

ODFL

PANW

SCCO

TSLA

Marjorie Taylor Greene Loads Up On Meta, Amazon, Tesla, Nvidia And Other Stocks As Donald Trump's New Equations With Big Tech Leaders Sets Stage For Growth: What Is At Stake? (UPDATED)

Deep-pocketed investors have adopted a bearish approach towards Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LLY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 21 extraordinary options activities for Eli Lilly. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 23% leaning bullish and 66% bearish. Among these notable options, 4 are puts, totaling $432,164, and 17 are calls, amounting to $1,185,751.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $460.0 to $1000.0 for Eli Lilly during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Eli Lilly's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly's whale trades within a strike price range from $460.0 to $1000.0 in the last 30 days. 
<h3>Eli Lilly Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738077326_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$50.0</td>
<td>$48.8</td>
<td>$48.8</td>
<td>$780.00</td>
<td>$244.0K</td>
<td>1.4K</td>
<td align="right">51</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/31/25</td>
<td>$9.75</td>
<td>$8.7</td>
<td>$8.7</td>
<td>$815.00</td>
<td>$185.7K</td>
<td>5</td>
<td align="right">208</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$173.2</td>
<td>$170.2</td>
<td>$170.2</td>
<td>$800.00</td>
<td>$170.2K</td>
<td>163</td>
<td align="right">10</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$153.9</td>
<td>$152.3</td>
<td>$153.9</td>
<td>$660.00</td>
<td>$153.9K</td>
<td>51</td>
<td align="right">10</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$40.55</td>
<td>$38.3</td>
<td>$40.55</td>
<td>$720.00</td>
<td>$101.3K</td>
<td>389</td>
<td align="right">25</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
After a thorough review of the options trading surrounding Eli Lilly, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Eli Lilly</h3>
<ul>
<li>With a volume of 339,987, the price of LLY is down -0.05% at $807.75. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 9 days.</li>
</ul>
<h3>Professional Analyst Ratings for Eli Lilly</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $1080.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Eli Lilly, targeting a price of $970. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on Eli Lilly with a target price of $1190. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Market Whales and Their Recent Bets on LLY Options

During the last three months, 7 analysts shared their evaluations of Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $1035.29, along with a high estimate of $1190.00 and a low estimate of $970.00. Highlighting a 5.02% decrease, the current average has fallen from the previous average price target of $1090.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1738069255_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Eli Lilly's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$970.00</td>
<td>$1000.00</td>
</tr>
<tr>
<td>Peter Verdult</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1190.00</td>
<td>$1250.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$997.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexandria Hammond</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$1000.00</td>
<td>-</td>
</tr>
<tr>
<td>James Shin</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1015.00</td>
<td>$1025.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$975.00</td>
<td>$1025.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1100.00</td>
<td>$1150.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Eli Lilly. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Eli Lilly compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Eli Lilly's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Eli Lilly's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LLY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Eli Lilly analyst ratings.</a>
<h2>All You Need to Know About Eli Lilly</h2>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Financial Insights: Eli Lilly</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Over the 3 months period, Eli Lilly showcased positive performance, achieving a revenue growth rate of 20.43% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Eli Lilly's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 8.48%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Eli Lilly's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 6.98%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Eli Lilly's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.32%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.19, caution is advised due to increased financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Eli Lilly: Insights From 7 Financial Analysts

Erste Group upgraded Eli Lilly (LLY) to Buy from Hold. Eli Lilly has products that are in high demand as well as "an extensive pipeline of potentia...

Eli Lilly upgraded to Buy from Hold at Erste Group

Fidelity Contrafund Q4 2024 Review

Eli Lilly Non-GAAP EPS of $5.51 beats by $0.43, revenue of $13.53B beats by $100M

Eli Lilly Non-GAAP EPS of $5.32 beats by $0.24, revenue of $13.53B beats by $100M

Earnings Snapshot: Eli Lilly tops Q4 consensus and FY2025 outlook

Eli Lilly in charts: Mounjaro, Zepbound, and Jardiance drive sales growth in Q4

Eli Lilly records over twofold rise in diabetes/ obesity drugs in Q4

Eli Lilly and Company reported a robust revenue growth of 45% in Q4 2024, reaching $13.53 billion, driven by increased volume from key products.

Eli Lilly's Q4 2024 Revenue Surges By 45% To $13.53 Billion

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS – Peloton (PTON) up 17% Tapestry (TPR) up 15% P...

Morning Movers: Roblox sinks following fourth quarter results and guidance

4 stocks to watch on Thursday: HON, AMZN and more

AAPL

AVGO

MSFT

NFLX

PTON

QCOM

RDDT

REGN

TTWO

Screenshot 2024-11-20 at 6.30.30 PM

BRTX

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Screenshot 2024-02-24 at 12.03.42 AM

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Screenshot 2024-02-22 at 11.51.01 PM

BTTX

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Press Releases

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)

Comments

Eli Lilly

Eli Lilly (LLY) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌